The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

19 May 2010 15:32

RNS Number : 2180M
Cathay International Holdings Ld
19 May 2010
 



 

19 May 2010

 

Cathay International Holdings Limited

Interim Management Statement

 

Cathay International Holdings Limited (the "Company") announces its Interim Management Statement for the period from 1 January 2010 to 14 May 2010:

 

Highlights of the period

 

·; On 21 January 2010, the Company announced, inter alia, the appointment of Mr. Lee Jin Yi as an executive director and Chief Executive Officer of the Company and the appointment of Mr Eric Siu as Finance Director of the Company.

 

·; On 12 February 2010, the Company announced further investments in Xian Haotian Bio-Engineering Technology Co. Limited ("Xian Haotian") and its subsidiaries and related companies (the "Xian Haotian Group").

 

·; On 1 April 2010, the Company announced the flotation of Lansen Pharmaceutical Holdings Company Limited ("Lansen"), a subsidiary of the Company, on the Hong Kong Stock Exchange, and the associated partial disposal of Lansen.

 

·; On 27 April 2010, the Company announced the preliminary annual results of the Group for the year ended 31 December 2009.

 

·; On 6 May 2010, the Company announced the successful closing of the placing and public offer of shares in Lansen.

 

Further investments in the Xian Haotian Group

 

On 12 February 2010, the Company announced further investments in the Xian Haotian Group, following which Xian Haotian is now an indirectly wholly owned subsidiary of the Company. The investment made in the Xian Haotian Group during the period was approximately US$13 million, which brings the total investment made to date to approximately US$33 million.

The Xian Haotian Group is one of the Company's major investments in the healthcare and pharmaceutical sector in China. Going forward, inositol will be the core product of the Xian Haotian Group, and the Company anticipates that the inositol business will become a major contributor to the growth in the Group's profits in 2011 and beyond. The inositol project is expected to commence production in the second half of 2010.

 

Flotation and Partial Disposal of Lansen

 

As announced on 6 May 2010, the public offer of shares in Lansen was approximately 852 times oversubscribed and the flotation offer price was set at HK$3.91 per share. The net proceeds of the flotation payable to Lansen, after deducting fees and expenses, were approximately HK$350.4 million (US$45.1 million). The net proceeds of the partial disposal received by the Company were approximately HK$114.9 million (US$14.8 million). Dealings in Lansen's shares on the Hong Kong Stock Exchange commenced on 7 May 2010.

 

Following completion of the flotation and the partial disposal, the Company indirectly holds approximately 52.46% of Lansen. Assuming that the over-allocation option provided under the terms of the flotation is exercised in full, the Company will indirectly hold approximately 50.56% of Lansen.

 

The effect of the flotation and partial disposal on the financial position of the Group has been an increase in net assets.

 

The financial performance of the Group in the period since the 2009 year end have been in line with the Company's expectations, and the outlook for the full year remains unchanged that expressed in our preliminary announcement of results on 27 April 2010.

 

Except for the further investment in the Xian Haotian Group and the net proceeds received from the flotation and partial disposal of Lansen, there has been no significant change to the financial position of the Group since that reported as at 31 December 2009.

 

 

For further information, please contact:

 

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

(via Brunswick)

020 7404 5959

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZKLFFBEFLBBK
Date   Source Headline
1st Dec 20205:39 pmRNSCompulsory Acquisition Notice
11th Nov 20209:46 amRNSResults of the Tender Offer
3rd Nov 202010:53 amRNSResult of SGM and Notification of change to Shares
3rd Nov 202010:08 amRNSLansen's seventh share reduction plan of Starry
2nd Nov 202010:11 amRNSDisposal of Starry Shares
29th Oct 202010:43 amRNSTotal Voting Rights
16th Oct 20206:16 pmRNSTender Offer and Notice of SGM
29th Sep 20201:14 pmRNSRequisition Notice
22nd Sep 202010:41 amRNSResults of Annual General Meeting
28th Aug 202012:10 pmRNSInterim Results
28th Aug 202011:57 amRNSNotice of AGM
27th Aug 20202:33 pmRNSLansen's Interim Results
21st Aug 202011:06 amRNSSecond Price Monitoring Extn
21st Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amRNSNotice of Interim Results 2020
3rd Aug 202011:21 amRNSBLOCK LISTING SIX MONTHLY RETURN
23rd Jul 20209:50 amRNSDisposal of Starry Shares
22nd Jul 202011:46 amRNSDisposal of Starry Shares
17th Jul 202012:12 pmRNSDisposal of Starry Shares
14th Jul 202010:09 amRNSTRANSFER OF LISTING
13th Jul 202011:17 amRNSPoll results of Lansen’s EGM
24th Jun 202010:46 amRNSDespatch of Circular by Lansen
15th Jun 202010:32 amRNSResult of General Meeting (“GM”)
5th Jun 20209:52 amRNSLansen update re Proposed Disposal
29th May 20202:18 pmRNSTotal Voting Rights
28th May 20202:49 pmRNSProposed transfer of listing and Notice of GM
21st May 20202:44 pmRNSTR-1: Notification of major holdings
20th May 20205:20 pmRNSTR-1: Notification of major holdings
18th May 20201:34 pmRNSDirector/PDMR Shareholding
24th Apr 20201:02 pmRNSPublication of Prospectus
21st Apr 20209:07 amRNSPublication and posting of Annual Report
9th Apr 202010:51 amRNSLansen's sixth share reduction plan of Starry
1st Apr 202010:39 amRNSAnnual Results for the year ended 31 December 2019
31st Mar 20202:37 pmRNSLansen reports annual results year ended 31 Dec 19
18th Mar 20207:00 amRNSNotice of Results
28th Feb 20207:00 amRNSTotal Voting Rights
11th Feb 20202:36 pmRNSTrading Update
3rd Feb 20207:00 amRNSBlock listing Six Monthly Return
30th Jan 20207:00 amRNSTreasury Shares,Share Capital,Total Voting Rights
27th Dec 20199:19 amRNSIncrease in shareholder loan
20th Dec 201911:36 amRNSUpdate re Board of Directors
12th Dec 201911:29 amRNSDisposal of Starry Shares
22nd Nov 201911:31 amRNSNew shareholder loan
31st Oct 20199:57 amRNSRetirement of an Executive Director
31st Oct 20197:12 amRNSTotal Voting Rights
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 201910:36 amRNSDisposal of Starry Shares
18th Sep 201912:10 pmRNSDisposal of Starry Shares
11th Sep 201911:37 amRNSLansen's fifth share reduction plan of Starry
10th Sep 20193:10 pmRNSDisposal of Starry Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.